Andrew Wachtel
Overview
Explore the profile of Andrew Wachtel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goebel C, Louden C, McKenna Jr R, Onugha O, Wachtel A, Long T
BMC Cancer
. 2020 Feb;
20(1):137.
PMID: 32085733
Background: In a previous study (Goebel et. al, Cancer Genomics Proteomics 16:229-244, 2019), we identified 33 biomarkers for an early stage (I-II) Non-Small Cell Lung Cancer (NSCLC) test with 90%...
2.
Goebel C, Louden C, McKenna Jr R, Onugha O, Wachtel A, Long T
Cancer Genomics Proteomics
. 2019 Jun;
16(4):229-244.
PMID: 31243104
Background/aim: In 2016 in the United States, 7 of 10 patients were estimated to die following lung cancer diagnosis. This is due to a lack of a reliable screening method...
3.
Kerwin E, Wachtel A, Sher L, Nyberg J, Darken P, Siddiqui S, et al.
Respir Med
. 2018 Jun;
139:39-47.
PMID: 29858000
Objectives: This randomized, double-blind, placebo-controlled, cross-over, Phase II dose-ranging study investigated the efficacy and safety of GP MDI (glycopyrronium administered by metered dose inhaler formulated using co-suspension delivery technology) compared...
4.
Crim C, Dransfield M, Bourbeau J, Jones P, Hanania N, Mahler D, et al.
Ann Am Thorac Soc
. 2014 Dec;
12(1):27-34.
PMID: 25490706
Rationale: Radiographically confirmed pneumonia risk with inhaled corticosteroid use in chronic obstructive pulmonary disease (COPD) has not been assessed to date. Objectives: To determine the incidence of pneumonia, risk factors,...
5.
Dransfield M, Bourbeau J, Jones P, Hanania N, Mahler D, Vestbo J, et al.
Lancet Respir Med
. 2014 Jan;
1(3):210-23.
PMID: 24429127
Background: Whether the combination of a once-daily inhaled corticosteroid with a once-daily longacting β(2) agonist is more protective than a once-daily longacting β(2) agonist alone against exacerbations of chronic obstructive...